Windtree, a biotech-turned BNB treasury agency, is dealing with delisting from the Nasdaq on August 21.
Abstract
- Nasdaq is ready to delist Windtree on August 21, following non-compliance with its $1 share value rule
- Windtree’s inventory value misplaced 97.74% prior to now six months, to $0.11
- Delisting would make it a lot more durable for Windtree to achieve entry to public markets
Struggling biotech Windtree’s pivot to BNB treasuries may quickly come to an finish. On Tuesday, August 19, regulatory filings confirmed that Windtree, generally known as “BNB Microstrategy,” is dealing with imminent delisting on Nasdaq over non-compliance.
In response to the submitting with the Securities and Trade Fee, Nasdaq will delist Windtree on August 21. Particularly, Nasdaq firms should commerce above $1 per share, whereas Windtree, underneath the ticker WINT, is buying and selling at $0.11.
Critically, the transfer may place Windtree’s pivot to BNB treasuries in danger. Particularly, the Nasdaq itemizing successfully turns Windtree right into a leveraged play on BNB obtainable on the general public market. With out entry to the Nasdaq, it could be harder for common traders to amass Windtree’s inventory.
Struggling Windtree pivoted to BNB treasuries
Windtree, a biotech agency, introduced its pivot to a BNB treasury agency after years of gradual enterprise. Previously six months, its inventory value has fallen 97.74% to its present stage of $0.11.
On July 16, the corporate first introduced plans to buy $60 million value of BNB tokens from Construct and Construct Corp., with the potential to amass $140 million extra. This put the corporate’s complete financing as much as $200 million for its BNB treasury.
Only a week later, on July 24, the agency introduced securing one other $520 million in financing. $500 would come from an fairness line of credit score settlement with an undisclosed financeer, and one other $20 million from a direct inventory buy from Construct and Construct Corp.
